Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 9/20 | 0.43 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.43 |
| ▸ | CPB1 | P15086 | 2/20 | 0.41 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31509482 | 0.95 | CPB2 (0.43) | GSRCPB2RNPEPCPB1DNMT1 | |
| Trifluoroacetic Acid SCHEMBL31509512 | 0.86 | HRH4 (0.37) | GSRCPB2CPB1DNMT1KDM4E | |
| SCHEMBL30469023 | 0.85 | CPB2 (0.39) | GSRCPB2RNPEPCPB1ALDH1A1 | |
| SCHEMBL6939609 | 0.83 | GPR84 (0.43) | DNMT1KDM4EALDH1A1TP53GLA | |
| SCHEMBL30634818 | 0.81 | GPR84 (0.46) | DNMT1 | |
| SCHEMBL6940135 | 0.81 | GPR84 (0.46) | DNMT1 | |
| SCHEMBL6934782 | 0.81 | GPR84 (0.46) | DNMT1 | |
| SCHEMBL1574549 | 0.81 | GPR84 (0.46) | DNMT1 | |
| SCHEMBL43883 | 0.81 | GPR84 (0.46) | DNMT1 | |
| SCHEMBL29505890 | 0.81 | KDM4E (0.49) | DNMT1KDM4EALDH1A1TP53GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534324-B1 | TUMOR SPECIFIC OLIGOSACCHARIDE EPITOPES AND USE THEREOF | GLYKOS FINLAND OY (FI) | 2019-01-16 | — | — | EP | disclosed |
| US-20180055928-A1 | Tumor specific oligosaccharide epitopes and use thereof | GLYKOS FINLAND OY (FI) | 2018-03-01 | — | — | US | disclosed |
| US-20140234318-A1 | TUMOR SPECIFIC OLIGOSACCHARIDE EPITOPES AND USE THEREOF | GLYKOS FINLAND OY (FI) | 2014-08-21 | — | — | US | disclosed |
| US-8697061-B2 | Tumor specific oligosaccharide epitopes and use thereof | GLYKOS FINLAND OY (FI) | 2014-04-15 | — | — | US | disclosed |
| EP-2322209-A2 | Tumor specific oligosaccharide epitopes and use thereof | Glykos Finland Oy (FI) | 2011-05-18 | — | — | EP | disclosed |
| US-20060014672-A1 | Tumor specific oligosaccharide epitopes and use thereof | GLYKOS FINLAND OY (FI) | 2006-01-19 | — | — | US | disclosed |
| EP-1534324-A2 | TUMOR SPECIFIC OLIGOSACCHARIDE EPITOPES AND USE THEREOF | BioTie Therapies Ltd. (FI) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004017810-A2 | TUMOR SPECIFIC OLIGOSACCHARIDE EPITOPES AND USE THEREOF | BIOTIE THERAPIES CORP. (FI) | 2004-03-04 | — | — | WO | disclosed |
| EP-0487610-B1 | PROHORMONE CLEAVAGE SITE BLOCKING ANTIBODY | CHIRON CORP (US) | 2000-02-09 | — | — | EP | disclosed |
| EP-0491828-B1 | PEPTIDES FROM GTPase-ACTIVATING PROTEIN (GAP), DIAGNOSTIC AND THERAPEUTIC USE THEREOF | CHIRON CORP (US) | 1999-06-16 | — | — | EP | disclosed |
| WO-1989011548-A1 | IMMOBILIZED SEQUENCE-SPECIFIC PROBES | CETUS CORPORATION (US) | 1989-11-30 | — | — | WO | disclosed |
| WO-1989011547-A1 | METHOD FOR HLA DP TYPING | CETUS CORPORATION (US) | 1989-11-30 | — | — | WO | disclosed |
| WO-1989002932-A1 | A COVALENT OLIGONUCLEOTIDE-HORSERADISH PEROXIDASE CONJUGATE | CETUS CORPORATION (US) | 1989-04-06 | — | — | WO | disclosed |
| WO-1989002931-A1 | OLIGONUCLEOTIDE FUNCTIONALIZING REAGENTS AND METHODS | CETUS CORPORATION (US) | 1989-04-06 | — | — | WO | disclosed |
| EP-0305409-A1 | SOLUBILIZATION OF PROTEINS FOR PHARMACEUTICAL COMPOSITIONS USING POLYPROLINE CONJUGATION. | CETUS CORP (US) | 1989-03-08 | — | — | EP | disclosed |
| US-4798787-A | POLYCLONAL | CETUS CORPORATION (US) | 1989-01-17 | — | — | US | disclosed |
| US-4762706-A | ANTICANCER | CETUS CORPORATION (US) | 1988-08-09 | — | — | US | disclosed |
| WO-1988003412-A1 | SOLUBILIZATION OF PROTEINS FOR PHARMACEUTICAL COMPOSITIONS USING POLYPROLINE CONJUGATION | CETUS CORPORATION (US) | 1988-05-19 | — | — | WO | disclosed |
| EP-0177814-A2 | Peptide antibodies and their use in detecting oncogene products | CETUS CORPORATION (US) | 1986-04-16 | — | — | EP | disclosed |
| EP-0175360-A2 | Peptide antibodies and their use in detecting oncogene products | CETUS CORPORATION (US) | 1986-03-26 | — | — | EP | disclosed |